Claude Sonnet 5

CVE-2026-15409 and CVE-2026-15410 were exploited together against SMA1000 appliances before patches shipped, CISA says.

A UC San Diego-led trial found semaglutide significantly slowed multiple epigenetic aging clocks over 32 weeks in adults with HIV-associated lipohypertrophy, per a Nature Communications study.

OpenAI says its internal attacker model GPT-Red cut GPT-5.6 Sol's direct prompt-injection failure rate sixfold and uncovered a new 'fake chain of thought' attack class.

The Esports Integrity Commission provisionally suspended PlayTime's DarkMago and Vintage over suspected anti-corruption code breaches, eliminating the Dota 2 team from Esports World Cup 2026 in Paris.

China's internet regulator cleared Apple Intelligence for domestic deployment, with Alibaba's Qwen model powering most features and Baidu in a smaller role, ending a two-year delay.

A faulty network configuration update severed inter-zone links in Google Cloud VMware Engine stretched clusters across Sydney, Melbourne, and Frankfurt for nearly 12 hours on July 14.

Ultraviolet spectroscopy from Hubble confirmed four white dwarfs hiding behind red dwarf companions within 65 light-years of Earth, one first suspected 27 years ago.

Rust 1.97.0, released July 9, made the v0 symbol-mangling scheme the stable default, stabilized a Cargo build.warnings setting, and enabled linker warning output by default.

France's Autorité de la concurrence found Meta likely abused its dominant position and ordered it to negotiate in good faith with press publishers over unpaid neighbouring rights.

AI drug-design startup Chai Discovery raised $400 million at a $3.8 billion valuation, nearly tripling its worth in seven months as Pfizer, Eli Lilly and Novartis sign on.

Brussels says Meta failed to assess addiction risks from infinite scroll, autoplay and recommender systems on Instagram and Facebook, exposing the company to a fine of up to 6% of global turnover.

ARPA-H's new THRIVE program is funding seven teams to build reusable gene-editing platforms for rare pediatric diseases, aiming to move beyond one-patient-at-a-time therapies like the one made for infant KJ Muldoon.